MedTrace Logo

Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer

NCT02987777 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2016-12-09

No results posted yet for this study

Summary

The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)

Conditions

Sponsors & Collaborators

  • Institut de Cancérologie de Lorraine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-08-31
Completion
2016-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987777 on ClinicalTrials.gov